Evofem Biosciences (EVFM) Competitors $0.0098 0.00 (-2.00%) As of 03:54 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsSustainabilityTrends EVFM vs. BPTH, TNFA, OGEN, ATXI, CELZ, FRTX, CPHI, ENVB, UPXI, and THARShould you be buying Evofem Biosciences stock or one of its competitors? The main competitors of Evofem Biosciences include Bio-Path (BPTH), TNF Pharmaceuticals (TNFA), Oragenics (OGEN), Avenue Therapeutics (ATXI), Creative Medical Technology (CELZ), Fresh Tracks Therapeutics (FRTX), China Pharma (CPHI), Enveric Biosciences (ENVB), Upexi (UPXI), and Tharimmune (THAR). These companies are all part of the "pharmaceutical products" industry. Evofem Biosciences vs. Bio-Path TNF Pharmaceuticals Oragenics Avenue Therapeutics Creative Medical Technology Fresh Tracks Therapeutics China Pharma Enveric Biosciences Upexi Tharimmune Evofem Biosciences (NASDAQ:EVFM) and Bio-Path (NASDAQ:BPTH) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability, community ranking, media sentiment and analyst recommendations. Which has more risk and volatility, EVFM or BPTH? Evofem Biosciences has a beta of -0.9, indicating that its stock price is 190% less volatile than the S&P 500. Comparatively, Bio-Path has a beta of 0.08, indicating that its stock price is 92% less volatile than the S&P 500. Do analysts recommend EVFM or BPTH? Bio-Path has a consensus target price of $20.00, suggesting a potential upside of 2,309.64%. Given Bio-Path's stronger consensus rating and higher possible upside, analysts clearly believe Bio-Path is more favorable than Evofem Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evofem Biosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Bio-Path 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor EVFM or BPTH? In the previous week, Bio-Path had 1 more articles in the media than Evofem Biosciences. MarketBeat recorded 1 mentions for Bio-Path and 0 mentions for Evofem Biosciences. Evofem Biosciences' average media sentiment score of 0.67 beat Bio-Path's score of 0.00 indicating that Evofem Biosciences is being referred to more favorably in the media. Company Overall Sentiment Evofem Biosciences Positive Bio-Path Neutral Which has preferable earnings & valuation, EVFM or BPTH? Evofem Biosciences has higher revenue and earnings than Bio-Path. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEvofem Biosciences$18.22M0.06$52.98M-$0.62-0.02Bio-PathN/AN/A-$16.08MN/AN/A Does the MarketBeat Community prefer EVFM or BPTH? Bio-Path received 20 more outperform votes than Evofem Biosciences when rated by MarketBeat users. However, 69.50% of users gave Evofem Biosciences an outperform vote while only 53.82% of users gave Bio-Path an outperform vote. CompanyUnderperformOutperformEvofem BiosciencesOutperform Votes26269.50% Underperform Votes11530.50% Bio-PathOutperform Votes28253.82% Underperform Votes24246.18% Is EVFM or BPTH more profitable? Bio-Path has a net margin of 0.00% compared to Evofem Biosciences' net margin of -46.42%. Evofem Biosciences' return on equity of -91.97% beat Bio-Path's return on equity.Company Net Margins Return on Equity Return on Assets Evofem Biosciences-46.42% -91.97% -61.93% Bio-Path N/A -2,842.40%-337.48% Do insiders and institutionals have more ownership in EVFM or BPTH? 0.2% of Evofem Biosciences shares are owned by institutional investors. Comparatively, 5.7% of Bio-Path shares are owned by institutional investors. 0.2% of Evofem Biosciences shares are owned by company insiders. Comparatively, 0.7% of Bio-Path shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. SummaryBio-Path beats Evofem Biosciences on 9 of the 15 factors compared between the two stocks. Get Evofem Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for EVFM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EVFM vs. The Competition Export to ExcelMetricEvofem BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.13M$6.56B$5.39B$9.14BDividend YieldN/A2.96%5.37%4.00%P/E Ratio-0.029.8288.2717.52Price / Sales0.06332.901,286.0780.21Price / CashN/A22.6336.6032.90Price / Book0.005.064.954.68Net Income$52.98M$154.90M$117.96M$224.57M7 Day PerformanceN/A2.61%2.54%3.26%1 Month PerformanceN/A1.56%3.49%5.30%1 Year PerformanceN/A5.65%27.05%22.74% Evofem Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EVFMEvofem Biosciences0.609 of 5 stars$0.01-2.0%N/A-74.5%$1.11M$18.22M-0.02120High Trading VolumeBPTHBio-Path1.4865 of 5 stars$0.93-1.7%$20.00+2,041.1%-89.9%$4.02MN/A0.0010Analyst ForecastNews CoverageTNFATNF PharmaceuticalsN/A$1.45+14.6%N/AN/A$4.00MN/A0.006Positive NewsHigh Trading VolumeOGENOragenicsN/A$0.33-5.2%N/AN/A$3.97M$40,000.00-0.055News CoverageATXIAvenue Therapeutics2.9599 of 5 stars$1.90+4.9%N/A-82.4%$3.90MN/A0.104Positive NewsHigh Trading VolumeCELZCreative Medical TechnologyN/A$2.23+2.8%N/A-46.3%$3.90M$11,000.00-0.595Positive NewsGap UpFRTXFresh Tracks TherapeuticsN/A$0.65-8.6%N/A-32.7%$3.88M$10.06M-0.4620Gap DownCPHIChina PharmaN/A$0.20-8.5%N/A-54.8%$3.87M$5.54M0.00231News CoverageGap DownENVBEnveric Biosciences3.1538 of 5 stars$0.38-6.7%$10.00+2,565.2%-67.5%$3.82MN/A-0.1520Gap DownUPXIUpexi2.4408 of 5 stars$3.66-4.9%$25.00+583.1%-85.5%$3.81M$22.08M0.00130Positive NewsGap DownTHARTharimmune2.946 of 5 stars$1.93-5.9%$17.00+780.8%-65.5%$3.73MN/A0.002Positive NewsGap DownHigh Trading Volume Related Companies and Tools Related Companies Bio-Path Alternatives TNF Pharmaceuticals Alternatives Oragenics Alternatives Avenue Therapeutics Alternatives Creative Medical Technology Alternatives Fresh Tracks Therapeutics Alternatives China Pharma Alternatives Enveric Biosciences Alternatives Upexi Alternatives Tharimmune Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:EVFM) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredThis coin could surge during Trump’s first week in office.Juan has never had a losing trade on Bitcoin. And he booked gains of 312% on Chainlink … Now, he says one v...Weiss Ratings | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evofem Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evofem Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
